Scarica l'app Stockscreener
82.84
1.56%
-1.31
Dopo l'orario di chiusura:
82.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.15
Aprire:
$84.05
Volume 24 ore:
3.88M
Relative Volume:
0.87
Capitalizzazione di mercato:
$48.64B
Reddito:
$5.88B
Utile/perdita netta:
$1.34B
Rapporto P/E:
35.32
EPS:
2.3455
Flusso di cassa netto:
$577.90M
1 W Prestazione:
+0.18%
1M Prestazione:
+7.49%
6M Prestazione:
+10.29%
1 anno Prestazione:
+24.22%
Intervallo 1D:
$82.53
$84.54
Intervallo di 1 settimana:
$80.24
$87.09
Portata 52W:
$64.89
$87.09
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
82.84 | 49.40B | 5.88B | 1.34B | 577.90M | 2.3455 |
|
ABT
Abbott Laboratories
|
124.54 | 218.75B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.90 | 146.52B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
357.67 | 138.67B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.40 | 115.97B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
What does recent volatility data suggest for Edwards Lifesciences CorporationJuly 2025 Macro Moves & Community Supported Trade Ideas - newser.com
FTC Wants 'Tainted' Drs. Testimony Barred From Merger Case - Law360
Will Edwards Lifesciences Corporation (EWL) stock test record highs in 2025Short Setup & Low Drawdown Momentum Ideas - newser.com
What is the fair value estimate for Edwards Lifesciences Corporation (EWL) stock in 2025July 2025 Final Week & Expert Approved Trade Ideas - newser.com
Edwards Lifesciences Corporation $EW Shares Sold by Huntington National Bank - MarketBeat
Edwards Lifesciences Corp. Hits New 52-Week High at $87.09 - Markets Mojo
Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Edwards Lifesciences Corporation stock reacts to new regulationsQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - newser.com
Edwards Lifesciences’ ALTERRA Study: A Potential Game-Changer in Heart Valve Treatment - MSN
Edwards Lifesciences (NYSE:EW) Given New $90.00 Price Target at Truist Financial - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Bank of New York Mellon Corp - MarketBeat
Wellington Shields Capital Management LLC Sells 5,700 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
EPO and UPC align in decision to uphold Edwards Lifesciences’ heart valve patent - JUVE Patent
36,530 Shares in Edwards Lifesciences Corporation $EW Purchased by Burney Co. - MarketBeat
What is the fair value of Edwards Lifesciences Corporation stock nowMarket Risk Summary & Fast Moving Market Watchlists - newser.com
Envestnet Asset Management Inc. Has $26.61 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Truist Securities Maintains Edwards Lifesciences (EW) Rating, Ra - GuruFocus
Bernstein Adjusts Price Target on Edwards Lifesciences to $90 From $85 - MarketScreener
Is Edwards Lifesciences Corporation (EWL) stock positioned for secular growth2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Bernstein raises Edwards Lifesciences stock price target to $90 on TAVR growth - Investing.com
Canaccord Genuity raises Edwards Lifesciences stock price target on solid Q3 - Investing.com
Raymond James upgrades Edwards Lifesciences stock rating to Outperform By Investing.com - Investing.com Canada
Machina Capital S.A.S. Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Welch & Forbes LLC - MarketBeat
Edwards Lifesciences Corporation $EW Shares Bought by Telos Capital Management Inc. - MarketBeat
South Dakota Investment Council Has $13.38 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Can Edwards Lifesciences Corporation stock sustain institutional interestInsider Selling & Weekly High Return Stock Opportunities - newser.com
Will Edwards Lifesciences Corporation stock outperform foreign stocksJuly 2025 Highlights & Fast Entry High Yield Tips - newser.com
Raymond James upgrades Edwards Lifesciences stock rating to Outperform - Investing.com
Edwards Lifesciences Reports Strong Earnings and Growth - MSN
Can Edwards Lifesciences Corporation stock survive global slowdownMarket Performance Recap & Consistent Profit Alerts - newser.com
Strs Ohio Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Amalgamated Bank Has $8.86 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation stock trend forecast2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Edwards Lifesciences Corporation (NYSE:EW) Q3 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences' (EW) Overweight Rating Reaffirmed at Piper Sandler - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 at Royal Bank Of Canada - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $92.00 - MarketBeat
Mccarter Private Wealth Services LLC Reduces Position in Edwards Lifesciences Corporation $EW - MarketBeat
Lockheed Martin Investment Management Co. Has $4.34 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Fisher Funds Management LTD Has $74.16 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Using data models to predict Edwards Lifesciences Corporation stock movementWeekly Trend Summary & Risk Controlled Stock Pick Alerts - newser.com
Spire Wealth Management Raises Position in Edwards Lifesciences Corporation $EW - MarketBeat
Quantitative breakdown of Edwards Lifesciences Corporation recent moveMarket Performance Report & Weekly Sector Rotation Insights - newser.com
Edwards Lifesciences Topped Estimates As Demand For Heart Devices Rose - Finimize
Edwards Lifesciences (NYSE:EW) Updates Q4 2025 Earnings Guidance - MarketBeat
Edwards Lifesciences (NYSE:EW) Announces Quarterly Earnings Results - MarketBeat
Edwards Lifesciences Lifts Outlook After Topping Expectations - Finimize
Edwards Lifesciences (EW) Target Price Raised by Barclays to $99 - GuruFocus
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
3.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):